Papers - HATAKEYAMA SHINGO
-
A Novel Strategy for Evasion of NK Cell Immunity by Tumours Expressing Core2 O-glycans.
Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, Hashimoto Y, Yoneyama T, Mori K, Koie T, Nakamura T, Saitoh H, Yamaya K, Funyu T, Fukuda M and Ohyama C.
EMBO J 2011.6
-
Perioperative Factors Associated With Postoperative Delirium in Patients Undergoing Noncardiac Surgery: An Individual Patient Data Meta-Analysis.
Sadeghirad B, Dodsworth BT, Schmutz Gelsomino N, Goettel N, Spence J, Buchan TA, Crandon HN, Baneshi MR, Pol RA, Brattinga B, Park UJ, Terashima M, Banning LBD, Van Leeuwen BL, Neerland BE, Chuan A, Martinez FT, Van Vugt JLA, Rampersaud YR, Hatakeyama S, Di Stasio E, Milisen K, Van Grootven B, van der Laan L, Thomson Mangnall L, Goodlin SJ, Lungeanu D, Denhaerynck K, Dhakharia V, Sampson EL, Zywiel MG, Falco L, Nguyen AV, Moss SJ, Krewulak KD, Jaworska N, Plotnikoff K, Kotteduwa-Jayawarden S, Sandarage R, Busse JW, Mbuagbaw L.
2023.8
-
Endothelial heparan sulfate controls chemokine presentation in recruitment of lymphocytes and dendritic cells to lymph nodes.
Bao X, Moseman EA, Saito H, Petryanik B, Thiriot A, Hatakeyama S, Ito Y, Kawashima H, Yamaguchi Y, Lowe JB, von Andrian UH, Fukuda M.
Immunity. 2010.11
-
Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase.
Bao X, Kobayashi M, Hatakeyama S, Angata K, Gullberg D, Nakayama J, Fukuda MN, Fukuda M.
Proc Natl Acad Sci U S A. 21 ( 7 ) 12109 - 12114 2009.7
-
Identification of mRNA splicing factors as the endothelial receptor for carbohydrate-dependent lung colonization of cancer cells
Hatakeyama S, Kazuhiro Sugihara, Jun Nakayama , Tomoya O. Akama, Suk-Man Annie Wong, Hiroto Kawashima, Jianing Zhang , David F. Smith, Chikara Ohyama, Minoru Fukuda, and Michiko N. Fukuda.
Proc Natl Acad Sci U S A. 106 ( 9 ) 3095 - 3100 2009.3
-
Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.
Mori K, Hatakeyama S, Enokida H, Miyake H, Kikuchi E, Nishiyama H, Ichikawa T, Kamai T, Kaji Y, Kume H, Kondo T, Matsuyama H, Masumori N, Kawauchi A, Takenaka A, Uemura H, Eto M, Nonomura N, Fujii Y, Hinotsu S, Ohyama C.
2024.3
-
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2
Kikuchi Y, Shimada H, Yamasaki F, Yamashita T, Araki K, Horimoto K, Yajima S, Yashiro M, Yokoi K, Cho H, Ehira T, Nakahara K, Yasuda H, Isobe K, Hayashida T, Hatakeyama S, Akakura K, Aoki D, Nomura H, Tada Y, Yoshimatsu Y, Miyachi H, Takebayashi C, Hanamura I, Takahashi H.
Int J Clin Oncol. 2024.3
-
Excess mortality in COVID-19-affected solid organ transplant recipients across the pandemic
2024.3
-
Incidence of postoperative cytomegalovirus and BK-polyoma virus infections and graft loss in ABO-incompatible renal transplant recipients: a multicenter retrospective study
Kodama H, Hatakeyama S, Matsuura T, Saito M, Nishida H, Hamaya T, Maita S, Murakami R, Tomita H, Saitoh H, Tsuchiya N, Habuchi T, Obara W, Ohyama C.
2024.2
-
Share Prognostic impact of histological discordance between transurethral resection and radical cystectomy
Matsuda A, Taoka R, Miki J, Saito R, Fukuokaya W, Hatakeyama S, Kawahara T, Fujii Y, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Iio H, Yasue K, Abe T, Nakanishi S, Matsumura M, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Matsui Y; Japanese Urological Oncology Group.
2024.2
-
Association between oral frailty and lower urinary tract symptoms among middle-aged and older adults in community-dwelling individuals: a cross-sectional study.
Yoneyama F, Okamoto T, Tamura Y, Ishii N, Togashi K, Soma O, Fujita N, Yamamoto H, Hatakeyama S, Kobayashi W, Ohyama C.
2024.1
-
Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy.
Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Bando Y, Nishiyama N, Kimura T, Yamashita S, Kitamura H, Miyake H; Japanese Urological Oncology Group.
2024.1
-
Impact of timing of rejection episode on cardiovascular events in living donor kidney transplantation: a multicenter retrospective study.
Okamoto T, Hatakeyama S, Hamaya T, Matsuura T, Saito M, Nishida H, Maita S, Murakami R, Tomita H, Saitoh H, Tsuchiya N, Habuchi T, Obara W, Ohyama C.
2023.12
-
Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study.
Sazuka T, Matsushita Y, Sato H, Osawa T, Hinata N, Hatakeyama S, Numakura K, Ueda K, Kimura T, Takahashi M, Tanaka H, Kawasaki Y, Kurahashi T, Kato T, Fujita K, Miyake M, Kojima T, Kitamura H, Miyake H, Ichikawa T.
2023.11
-
Trends in the use of local intervention for metastatic hormone-naïve prostate cancer: A multicenter retrospective study.
Tanaka R, Hatakeyama S, Narita S, Sakurai T, Tanaka T, Miura H, Oishi T, Kawamura S, Hoshi S, Ishidoya S, Mitsuzuka K, Ito A, Tsuchiya N, Habuchi T, Ohyama C.
2023.11
-
Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.
Kobayashi M, Numakura K, Hatakeyama S, Ishida T, Koizumi A, Tadachi K, Igarashi R, Takayama K, Muto Y, Sekine Y, Sobu R, Sasagawa H, Akashi H, Kashima S, Yamamoto R, Nara T, Saito M, Narita S, Ohyama C, Habuchi T.
2023.11
-
Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group.
Horie S, Naito S, Hatakeyama S, Kandori S, Numakura K, Kato R, Koguchi T, Myoen S, Kawasaki Y, Ito A, Adachi H, Kojima Y, Obara W, Habuchi T, Nishiyama H, Ohyama C, Tsuchiya N.
2023.11
-
The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database.
Koguchi T, Naito S, Hatakeyama S, Numakura K, Muto Y, Kato R, Kojima T, Kawasaki Y, Morozumi K, Kandori S, Kawamura S, Nishiyama H, Ito A, Habuchi T, Obara W, Ohyama C, Tsuchiya N, Kojima Y.
2023.11
-
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Nishiyama N, Kita Y, Ito K, Kato M, Hatakeyama S, Matsushita Y, Naito S, Miyake M, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Nishiyama H, Kobayashi T, Kitamura H; Japan Urological Oncology Group.
2023.11
-
Humoral response to SARS-CoV-2 mRNA vaccine on in ABO blood type incompatible kidney transplant recipients treated with low-dose rituximab.
Hamaya T, Hatakeyama S, Yoneyama T, Tobisawa Y, Kodama H, Fujita T, Murakami R, Mori K, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Saitoh H, Narumi S, Tomita H, Ohyama C.
Sci Rep. 2023.9